Martial S. Involvement of ion channels and transporters in carcinoma angiogenesis and metastasis.
CARCINOMA IS A SOLID CANCER developing from epithelial cells and is the most widely spread form of human cancer. Among the phenomena leading to the development and progression of this type of cancer, one of the most important is angiogenesis. Indeed, tumor vascularization is essential for a growing tumor to obtain oxygen and nutrients needed for its ongoing growth, in situ. Tumor neovascularization is also a means for the tumor to grow away from its primary site towards a remote neocolonized structure (metastasis).
In the last 10 to 15 years, many efforts have been made on the elucidation of which genes might be directly involved or affected during the different steps of tumorogenesis, described by Hanahan and Weinberg (95, 96) as the hallmarks of cancer. Multiple studies demonstrated that, among these genes, plasma membrane ion channels and transporters are clearly modulated during carcinogenesis, in different types of carcinomas (9, 20, 31, 75, 78, 93, 133, 147, 201, 207) . Several different roles have been ascribed to ion channels during carcinogenesis, depending on the step of the tumorization process and on the organ in which it takes place.
In this review, we do not intend to make an exhaustive list of channels involved in cancer development. Instead, we choose to focus on the involvement and/or alteration of some ion channels in angiogenesis, from the vascularization of recently formed tumors to the metastasis cascade. Indeed, neo-formation of tumors involves pH changes, which are associated with proton exchange through the plasma membrane (127, 209, 217) and water transport (17, 162) . The subsequent tumor growth needs neovascularization, associated with Ca 2ϩ , K ϩ , and Na ϩ channels (5, 61, 201) . Finally, Na ϩ , K ϩ , Ca ϩ , and Cl Ϫ channels are implicated in the transition to metastasis (32, 73, 75) .
The main ion channels involved in tumor development processes and mentioned in this review are listed in Table 1 .
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NEOANGIOGENESIS
The Fate of New Tumors
In the early steps of its formation, a tumor depends solely on the host blood vessels (104) . However, this initial peripheral vasculature quickly disappears, leaving the tumor and its microenvironment in a hypoxic state (84, 97) . Folkman (77) was the first to show that, under these conditions, the tumor growth is limited to a few cubic millimeters, unless reorganization of a new blood supply is promoted (neoangiogenesis).
The lowered local O 2 pressure (PO 2 ) observed near cancer cells and the resulting tumor microenvironment acidification activate hypoxia-inducible factors, especially HIF-1 (44, 58, 115) . HIF-1␣ is stabilized by phosphorylation (172) and dimerizes with the constitutively expressed HIF-1␤ to form the transcription factor HIF-1, which in turn stimulates a set of genes involved in tumor development. Conversely, recent reports present HIF-2 as the tumorigenic form of HIF, whereas HIF-1 would be a tumor suppressor (227, 263) .
Initially, the cancer cells undergo metabolic changes, among which increased glucose consumption and lactate production (the Warburg's effect) lead to acidosis of the cells. In conjunction with the higher need for glucose, several authors report a HIF-dependent expression of the GLUT-1 glucose transporter in breast or colorectal carcinoma cell (CRC) models (25, 84, 132) and a repressed mitochondrial function (175) . In clear cell renal cell carcinomas (ccRCC), some isoforms of glucose transporters are equally increased, including the GLUT-5 fructose transporter (240) . Moreover, to prevent acidosis induced by the accumulation of lactate, cancer cells increase the amount and/or activity of several families of acid-extruding plasma membrane proteins. In several carcinoma models, these HIF-1 increased proteins include: NHE1, the Na ϩ /H ϩ exchanger (79, 170, 231) ; the MCT1 and MCT4 forms of monocarboxylate transporters, dedicated to lactate extrusion (62, 184, 246) ; and the SLC4A4 (NBC) Na ϩ -HCO 3 Ϫ cotransporter (1, 180) , involved in the bicarbonate reabsorption which contributes to intracellular pH recovery. Acid-sensing ion channels (ASIC1, 2, 3) are also upregulated in adenoid cystic carcinomas, following the acidification of the extracellular space (257) . Finally, carbonic anhydrases [especially CAIX, the main carbonic anhydrase found in hypoxic tumors (64)], dedicated to microenvironment pH modulation, are also upregulated (132, 171, 180) . The different ion channels involved at this stage are summarized in Fig. 1 .Activation of all these transport proteins eventually contribute to a modest elevation of the tumor cell intracellular pH, while the extracellular medium is acidified.
Subsequently, the newly constituted tumor will only grow larger if it manages to regenerate a constant blood supply to provide O 2 and nutrients to the tumor cells and to rid the cells of metabolites. Two main families of plasma membrane ion channels have been proposed to be involved in this tumor developmental stage and regulated by HIF. Transient receptor potential (TRP) channels contribute to calcium homeostasis and are upregulated in several cancer cell types, thus playing an important part in Ca 2ϩ influx, regulatory volume decrease (RVD), and cell cycle progression (63, 254) . A variety of K ϩ channels are also involved in the HIF-induced regulation of proliferation and revascularization, namely the voltage-dependent "ether-à-gogo" potassium channel (EAG1, KCNH1, K v 10.1) (31, 177) , and the two-pore domain potassium channels TASK (30) and TREK (243) . In pancreatic ductal adenocarcinoma (PDAC), the Ca 2ϩ -dependent potassium channel of intermediate conductance, IK Ca (K Ca 3.1), is upregulated and contributes to cell proliferation (114) .
Angiogenic Switch
Tumor angiogenesis is the key step for tumor growth, invasion, and metastasis. Tumor angiogenesis mostly relies on the same processes as those involved in physiological angiogenesis (27, 45, 176) . Particularly, ischemia and hypoxia are in both cases, major initiators of angiogenesis processes ("on" switches). Moreover, tumor angiogenesis and physiological angiogenesis heavily depend on VEGF secretion, as was described elsewhere and as we will describe here for tumordepending angiogenesis. The main differences are as follows: 1) pathological angiogenesis is more dependent on VEGF than physiological angiogenesis (45); and 2) physiological angiogenesis events recede when vessel perfusion starts and upon disappearance of the stimuli that gave rise to neoangiogenesis ("off" switch), whereas tumor angiogenesis is a continuous process, fueled by the steady secretion of tumor-induced angiogenesis factors (45) .
The concept of "angiogenic switch" was formulated to characterize angiogenesis as a balance between processes that tend to favor and processes that tend to prevent angiogenesis (94) . When tumor cells enter a hypoxic state, activation of HIF leads to the subsequent activation of a multiple array of pro-angiogenic factors; thus, the regular balance of angiogenesis is lost: the angiogenic switch has been turned "ON". The most studied HIF-regulated pro-angiogenesis factor is probably VEGF, the angiogenesis cytokine that regulates endothelial cell proliferation and blood vessel formation. Both VEGF and its receptors VEGFR1 (FLT-1) and VEGFR2 (KDR/FLK1), which are located principally on the surface of endothelial cells, are upregulated by HIF (123, 185) . Fibroblast growth factor (FGF) is also regulated by hypoxia and may act synergistically with VEGF to amplify angiogenesis (125) .
The angiogenic switch is turned "ON" in several types of cancer cells, including mouse colon carcinoma, mouse melanoma, and human neuroblastoma, when several types of ion channels are modulated. P2X 7 R, the nonselective cationic pore, has been shown to promote tumor growth and VEGF release (4, 5, 7) . TRPC channels are functionally coupled to VEGF or FGF, playing important roles in cancer development steps (76, 156) . Moreover, in renal cell carcinoma (RCC), the TRPC4 Ca 2ϩ channel expression is decreased, which impairs Ca 2ϩ metabolism, hence preventing the production of thrombospondin-1 (TSP1), an angiogenesis inhibitor (238) . Numerous studies report overexpression of most families of K ϩ channels in human cancers. In particular, the closely related voltage-dependent hERG and EAG1 K ϩ channels are both involved in the processes leading to angiogenesis. Indeed, hERG channels regulate angiogenesis in CRC by increasing the HIF-1 activated VEGF expression and secretion in a signaling to promote endothelial cell proliferation and subsequent neoangiogenesis, which we largely discuss in the next section. However, it is noteworthy that some Ca 2ϩ channels, mostly of the TRP family, are upregulated by hypoxia in cancer cells (76) . The subsequent increase in intracellular Ca 2ϩ concentration is at the basis of cancer cell hallmarks such as cell proliferation or migration (76) .
Neovascularization
Tumor vasculature is a crucial feature of carcinoma development. New blood vessels develop by sprouting (angiogenesis) or intussusception from preexisting vessels (144, 199) . They can also emerge from the assembly of endothelial precursors derived from the bone marrow (vasculogenesis) (189) . Sprouting is a very well-studied process, which is involved in tumor blood vessel formation. Angiogenesis is a multistep process that begins when endothelial cell VEGF receptors are stimulated by VEGF (19, 34) to give rise to new blood vessels growing towards the avascular tumor that initially secreted the stimulating cytokine. The different steps of the process are detailed below.
VEGF-induced blood vessel dilatation. Most research on tumor angiogenesis has focused on VEGF-A. VEGF-A signaling occurs through two VEGF receptors, VEGFR1 and VEGFR2 (19, 144) . Although VEGF-A has the highest affinity for VEGFR1, the higher tyrosine kinase activity of VEGFR2 makes it the primary receptor involved in angiogenesis processes. VEGFR1, conversely, is involved in macrophage chemotaxis, as well as in tumor cell survival and invasion (136, 205, 255) . Additionally, VEGFR1 may also have a negative role on angiogenesis and tumorogenesis processes, only acting as a decoy receptor (102, 142) . VEGF-A binds to its receptor, and this first results in blood vessel dilatation, as recently shown by in vivo studies of breast tumors, by sonographic examination (41) . Like most mammalian cells, endothelial cells express cell-swelling activated Cl Ϫ channels, called the volume-regulated anion channel (VRAC) (166, 167) . Interestingly, receptor tyrosine kinases such as VEGFRs can serve as mechanosensors (40) . As such, they are involved in the VRAC signaling pathway. Thus, one might infer that VEGF signaling in endothelial cells is mediated by VRAC Cl Ϫ channels, as shown by the suppression of angiogenesis by VRAC inhibitors (146) . Disorganization of the vascular bed. Angiogenesis partly proceeds by the VEGF stimulation of endothelial cell matrix metalloproteinases (MMPs) (188) . Secretion of these MMPs, more precisely MMP-2 and MMP-9 (18, 250) , triggers the dissolution of the basement membrane surrounding these endothelial cells, thus provoking the destabilization of the entire blood vessel wall and leading to vessel leak (34) . Among the multiple mechanisms that cooperate for the close regulation of MMP activity, Ca 2ϩ signaling is one of the most important (121) . The work, led by Kato et al. (121) , demonstrates that, under extracellular acidification, the B16 mouse melanoma cell line displays increased voltage-gated Ca 2ϩ channel expression and activity, resulting in an increase in intracellular Ca 2ϩ concentration and in MMP-9 induction. Thus, Ca 2ϩ signals and channels are potentially the most important points in the regulation of the VEGF-triggered blood vessel reorganization. However, the work conducted by Kato and colleagues addresses the other types of Ca 2ϩ channels that may be involved in the complex processes going from VEGF upregulation to basement membrane disorganization. Indeed, under a hypoxic stimulus, the formation of a VEGF-VEGFR complex at the endothelial cell plasma membrane can also result in intracellular Ca 2ϩ increase, owing to the release of intracellular Ca 2ϩ stores (Fig. 2) . The depletion of these stores in turn results in Ca 2ϩ influx, via plasma membrane Ca 2ϩ channels, which results in store-operated calcium entry or SOCE (for review, see ref. 75 ). Several Ca 2ϩ channels of the TRP superfamily appear to be involved in SOCE and help explain how SOCE contributes to VEGF-induced basement membrane disruption. Among the TRPCs (canonical), TRPC1 activation magnifies the VEGF-induced increase in endothelial cell monolayer transepithelial permeability (111, 178) . Conversely, inhibition of the TRPC1 activity reduces this transepithelial permeability increase (111) . TRPC4 is a necessary intermediate in the response of human pulmonary artery endothelial cells to VEGF stimulation (71) . TRPC6 is also presented as a good candidate in the process of VEGF-induced vascular permeability increase. Indeed, as shown in individually perfused frog microvessels, stimulation of TRPC6 generates an increase in the hydraulic conductivity (L p ) of the vessels (186) . The Ca 2ϩ release-activated Ca 2ϩ (CRAC) channel [composed of the plasma membrane Orai1 subunit coupled with the endoplasmic reticulum (ER) STIM subunit] is also involved in VEGFdependent SOCE (139) . Indeed, in human umbilical vein endothelial cells, inhibition or disruption of Orai1 reduces VEGF-induced calcium entry, cell migration, and in vitro angiogenesis. The increase in transepithelial permeability may result from both in-cell and in-between-cell pore creation (43, 98) . Finally, VEGF effects can also occur via receptor-operated calcium entry (ROCE), as shown on human microvascular endothelial cells (42); TRPC3 and TRPC6 are two examples of channels involved in calcium-mediated vascular permeabilization.
In conclusion, VEGF-induced calcium-dependent events leading to the basement membrane disorganization, though resulting in the same final outcome, appear to be the consequence of several calcium entry pathways.
Endothelial cell proliferation, migration, and organization. Breakdown of the blood vessels (i.e., dissolution of the basement membrane) leads endothelial cells to be released into the extracellular matrix (ECM) where they proliferate and organize to generate new blood vessels, growing towards the tumor that initially emitted stimulating signals. Angiogenic sprouting is a guided process in which the vasculature expands outwards from the preexisting vessel, following a gradient of angiogenic factors such as VEGF-A (85) or soluble VEGFR1 (38) . In this regard, Gerhardt and colleagues (85) demonstrated that the first cell of the column, the so-called "endothelial tip cell," consists of a single, nonproliferative, highly polarized endothelial cell, which is the sensor of the emitted elongation signal. The cell migration along this signal (chemotaxis) paves a path for the cells that follow, the "stack cells," which undergo high rate mitosis to form the newly elongating blood vessel. At the endothelial cell level, it is now recognized that VEGFR2 is the main actor of the angiogenic cascade. VEGF, when binding to VEGFR2, activates a signaling cascade starting from autophosphorylation of VEGFR2, subsequent phosphorylation and activation of phospholipase C-␥ (PLC-␥), increased production of inositol 1,4,5-trisphosphate (IP 3 ) and resulting increase in the Ca 2ϩ release from endoplasmic reticulum. The subsequent rise in calcium influx by the aforementioned SOCE process involves TRPC channels, as already discussed (see Disorganization of the vascular bed section) and promotes endothelial cell migration via a Ca 2ϩ /calmodulin/calcineurin pathway (72) . The role of SOCE was also established in bovine artery endothelial cells for the different mechanisms of angiogenesis (i.e., cell sprouting, cell proliferation and cell migration) and involves the Ca 2ϩ /calmodulin/protein kinase cascade (15). One of the fundamental roles of ion channels in endothelial Ca 2ϩ signaling is the fine-tuning of the electrochemical gradient for Ca 2ϩ (118) . Several types of ion channels cooperate in elaborating the cell membrane potential, which regulates calcium entry into the endothelial cells (118) . Among those, K ϩ channels, especially Ca 2ϩ -activated K ϩ channels (251), inwardly rectifying K ϩ channels (K ir ), and voltage-dependent K ϩ channels, are the major classes of ion channels involved in setting the membrane potential (165) , which in turn influences the driving force for the Ca 2ϩ via SOCE. Indeed, blockers of K ϩ channels, as well as plasma membrane depolarization, stop the cell cycle in G 1 phase, thus reducing cell proliferation (153, 165) . However, among the Ca 2ϩ -dependent K ϩ channels, the Ca 2ϩ -dependent intermediate conductance K ϩ channel IK1 (SK4, KCNN4) increases cell proliferation with a completely different mechanism, in a HEK-overexpressing system. Indeed, the potassium current itself does not seem to mediate the effect, since a nontransporting mutant of the channel induces the same proliferation. So it seems that the IK1-induced proliferative effect is not SOCE mediated (152) . The cell membrane potential is partly regulated by Cl Ϫ channels (247). Hence, volume-regulated anion channels (VRAC), Ca 2ϩ -activated Cl Ϫ channels (CaCC), as well as cystic fibrosis transmembrane regulator (CFTR) (145) might be important regulators of SOCE, which drives the proliferation step of angiogenesis.
Maturation of the new blood vessel. Two steps are essential for completion of angiogenesis:
1) A new vessel is formed when the elongating sprout lumenizes to create a tube, which will eventually be able to transport fluid and the multiple blood components: this step is called tubulogenesis (117, 143) . At least two models of tubulogenesis have been described. The "cell hollowing" model (currently the most studied) evolves from a chain of single endothelial cells (117) . This model involves intracellular vesicle formation, then fusion of these vesicles into vacuoles, first intracellularly, and then from cell to cell, all along the sprout, when the vacuoles get bigger. The future lumen vacuole membrane finally acquires hallmarks of an apical membrane, thus defining the apical-basolateral polarity of the neo-formed vessel. In the less studied "cord hollowing" model, which happens in a multicellular elongated stack, the cells first lose their initial polarity, then basolateral membrane markers are accumulated at the membrane facing the extracellular matrix, while vesicles are accumulated and get fused on the opposite membrane, hence forming an initial lumen that expands afterwards (179, 248) . In the cell hollowing model, the formation of vacuoles is linked to the activation of intracellular chloride channels of the CLIC family. The chloride intracellular channel (CLIC) family of proteins contains six mammalian members (CLIC1-6), from which only CLIC1 and CLIC4 are expressed in endothelial cells (230) . CLIC proteins can change from a soluble state to a membrane-linked state. In the latter case, when inserted in such organelles as mitochondria, Golgi membranes, nuclear membranes, etc., CLICs function as chloride channels, although very different in structure from the other known Cl Ϫ channels (65, 233). In the cell hollowing model of tubulogenesis, CLIC4 is present in human umbilical vein endothelial cells and promotes several processes involved in angiogenesis, including luminal formation (229) . Particularly, endothelial cells derived from transgenic mice, in which the Clic4 gene has been invalidated, fail to proceed to the vacuole creation and extension process. Tung and colleagues (229) show that the enlarging vacuoles acidify during their formation, involving an electrogenic vacuolar proton-ATPase (vH ϩ -ATPase), and propose that CLIC4 supports this acidification by creating an electrical gradient for the proton transfer. The same article proposes that CLIC1 may partially compensate for the absence of CLIC4 in the process of tubulogenesis, although CLIC1 seems mainly committed to proliferation and migration processes rather than to morphogenesis of endothelial cells (230) .
2) The new hollow tube thus created is finally stabilized by the formation of a new basement membrane. Indeed, in physiological angiogenesis, accessory cells, such as pericytes and smooth muscle cells, are recruited to the newly developed vessel to form a new basement membrane (54). In tumor angiogenesis, however, the newly formed blood vessels are very heterogeneous in structure and function (54). Their architecture is very chaotic and disorganized, with abnormal branching, inflated cells, and tortuous courses. Subsequently, the association between endothelial and mural cells is altered, becoming loose and leading to highly permeable vessels, which, paradoxically, are not adapted to a fluent and regular irrigation of the tumor, hence favoring its dissemination to other, supposedly more welcoming, locations (35) . The leaky vessels allow the tumor to escape the noxious environment in which it grows (metastasis). Again, Ca 2ϩ channels of the TRP family, namely transient receptor potential vanilloid 4 (TRPV4) Ca 2ϩ channels, are key determinants in the balance between normal and defective vasculature (2) . Indeed, tumoral endothelial cells naturally contain low levels of TRPV4. Conversely, overexpression or pharmacological activation of TRPV4 normalizes the vasculature and restores the endothelial cell layer physical and biophysical properties.
METASTASIS
The Tumor Microenvironment: Role and Ion Channel Profile
The extracellular environment of tumor cells is viewed as a complex network of stromal cells, deregulated vasculature, extracellular membrane (ECM) proteins, growth factors, and cytokines, all of which are generated or activated by the tumor cells, acting together to influence the growth, behavior, and malignancy of the tumor (236) and constantly evolving while the tumor grows and becomes more aggressive. The physical and chemical characteristics of the tumor microenvironment (TME) is cancer-type dependent, but there are a number of typical, cancer type-independent features, among which are hypoxia, acidic pH, high levels of lactate, and low levels of glucose (21, 82) . In this context, ion channels and transporters are important specialized proteins involved in the regulation of signaling pathways associated with these properties. All the cells composing the TME are laden with several types of missexpressed/overexpressed ion channels, which participate in the crosstalk described by Arcangeli (8) , between the tumor and its TME. These ion channels also contribute to maintain the harsh conditions that allow tumor growth (33) . Concerning the vasculature, we have already discussed the channels involved in neoangiogenesis and mentioned the importance of endothelial cell Ca 2ϩ homeostasis throughout this process. Mesenchymal cells (fibroblasts, myofibroblasts, immune cells) also express ion channels, particularly lymphocytes that infiltrate the tumors express K ϩ channels of the K v 1.3 and K Ca 3.1 types, which are involved in T cell activation via Ca 2ϩ signaling (124) . Interestingly, tumor-associated macrophages express P2X 7 R nonselective cation channels and inwardly rectifying K IR K ϩ channels; both families are involved in the Ca 2ϩ -dependent activation of macrophages (8) .
Role of the Epithelial-Mesenchymal Transition in the Metastasis Process
Metastasis of epithelial cancer cells is a multistep process, which involves mobilization of the cells from their original location, migration of the cells, invasion of surrounding locations, intravasation of cancer cells into newly formed tumoral blood vessels, cell survival in the blood flow, and seeding to more distant new niches, where the cells start proliferating again, thus creating secondary tumors. Multiple oncogenic signals originating from the TME convert the cells into their new metastatic and invasive phenotype. These signals lead the tumor cells to acquire several biological capabilities described as hallmarks of cancer (95, 96) and mediated by an epithelialmesenchymal transition (EMT) process, otherwise called the metastatic cascade. During this cascade, cells, which originally display epithelial cell features [i.e., adhesion to each other and to the basement membrane, high level of E-cadherin involved in the epithelial integrity (16)], are progressively transformed into mesenchymal cells (116) . Briefly, during this process, polarized epithelial cells acquire a new phenotype, which includes increased resistance to death, enhanced migratory capacities, and invasiveness. The complete spectrum of signaling agents that contribute to EMT remains an open question. EMT is a complicated process, and ion channels from several different families play a particularly important role in this transition (249) .
Mobilization of the cells: involvement of ion channels. Loss of cell-cell contacts is the first step of EMT. This phenotype is associated with repression of cell junction proteins, such as E-cadherin, and correlated with stimulation of both vimentin (an intermediate filament protein) and N-cadherin (neural cadherin, normally expressed in migrating nontumoral cells) synthesis (107, 164, 226) . This process has been shown in breast cancer cells to be Ca 2ϩ dependent (52). In fact, induction of EMT is clearly related to the expression of TRPM7, the melastatin-like TRP Ca 2ϩ channel. Indeed, upregulation of TRPM7 regulates the expression of the EMT marker vimentin. Conversely, downregulation of the channel prevents EMT induction in breast cancer cells. In colorectal carcinoma cells, the Ca 2ϩ -activated KCNN4 (K Ca 3.1; SK4) channels have been shown to be involved in EMT promotion, probably through participation in the cell hyperpolarization, subsequent induction of Ca 2ϩ entry via voltage-dependent Ca 2ϩ channels, and an increase in intracellular Ca 2ϩ concentration (129) . Tumor cell mobilization is the next step in the metastatic cascade. This step involves migration of the cells from their initial site and invasion of the surrounding stroma and vasculature. This is a complex process requiring the coordination of multiple macromolecules involved in adhesion, cytoskeletal dynamics, and digestion of the ECM. Among the extracellular elements favoring EMT, hypoxia and microenvironment acidification have been the most studied and are involved in tumor cell mobilization. As discussed earlier in this review, tumor acidity is a direct result of hypoxia (83, 237) . Indeed, low PO 2 raises the rate of glycolysis, which produces elevated levels of lactate and protons in tumor cells. To maintain intracellular pH within a tight range (pH 7.2-7.4), the tumor cells upregulate H ϩ extrusion, which, in turn, results in microenvironmental acidosis, down to pH 6.5 (50) or even to pH 5.8 as shown in highly metastatic MDA-MB-435S breast tumor cells (208) . Extracellular acidosis increases even more due to hypoxiainduced activation of carbonic anhydrases, especially CAIX (223) . Consequently, tumor cells are equipped with mechanisms that allow them to sense and react to the low extracellular pH to which they have been exposed. pH sensors of several types are present in the plasma membrane of mammalian tumor cells, and these pH sensors are categorized into G protein-coupled receptors (GPCRs) and non-GPCR pH sensors (50). GPCR signaling pathways are manifold: ERK pathway/ Ca 2ϩ release (105), G s -protein/cAMP, G 12/13 -protein/Rho, and G q -protein/phospholipase C pathways (140) . pH sensing results in reorganization of the cytoskeleton (e.g., actin rearrangement, stress fiber synthesis, etc.), thus contributing to tumor migration and eventually to tumor progression (39) . Non-GPCR proteins include ion channels of several families and participate in migration and invasion phenotypes. Indeed, expression of the tumor cell cation-permeable acid sensing ion channels (ASICs) is pH dependent. ASIC1a is associated with tumor cell migration and invasion in hepatocellular carcinoma cells (112); ASIC2a and ASIC3 have been identified in the plasma membrane of adenoid cystic carcinoma cells and proposed to be involved in the acquired invasive capabilities of the cells (257) . The Ca 2ϩ channel TRPV1 is also activated by low pH (259) and is correlated with tumor cell proliferation in human prostate cancer cell lines (159) . Both families of channels are involved in cancer-associated pain (57, 259), and plasma membrane phospholipids are proposed to be modulators of ASIC and TRPV1 activities (128) .
Other acid-sensitive channels comprise several members of the Ca 2ϩ channel TRP family, ionotropic purinoceptors (P2X), inward rectifier K ϩ channels (K ir ), voltage-activated K ϩ channels (K v family), L-type Ca 2ϩ channels (Ca v , CACN), hyperpolarization-activated and cyclic nucleotide-gated cation channels (HCN), gap junction channels, and Cl Ϫ channels. They are involved in the process of tumor cell migration (217) . Interestingly, the Ca 2ϩ -activated, high conductance, BK Ca K ϩ channels are not involved in breast cancer progression, as shown by the absence of effect of iberiotoxin (an inhibitor of BK Ca ) in the processes of proliferation, survival, migration, or invasion in several breast cancer cell lines (200) .
Migratory cells are polarized along their longitudinal axis, with hypoxia-and TME acidosis-dependent protrusion of lamellipodia at the cell front edge and coordinated retraction of the rear edge (213) . This process is intracellular Ca 2ϩ concentration sensitive, thus involving Ca 2ϩ release from intracellular stores and SOCE channels (228) . It creates the amoeboid movement characteristic of migrating tumor cells which is highly dependent on ion and water flux (210) . Indeed, the formation of lamellipodia is accompanied by relocalization at the leading edge of a number of plasma membrane transport proteins, among which are CAIX, NHE, MCT (all involved in pH modulation), anion exchangers (such as NBC transporters or the anion exchanger AE2), and water channels (aquaporins; AQP). It is proposed that the coordinated action of all these channels and transporters makes it possible for the cells to establish the osmotic gradient that subsequently induces AQPmediated water flux at the leading edge of the cell. Water extrusion by AQP, at the rear end of the cell, is mediated by the combined activity of Ca 2ϩ -activated K ϩ channels (K Ca 3.1) and volume-regulated anion channels (VRACs) and leads to regulatory volume decrease (RVD) and shrinkage of the cells (206) .
Invasion of surrounding TME and vasculature. Invasion of healthy tissues by tumor cells is critically dependent on the local degradation of ECM and basement membrane, which otherwise would constitute a barrier to tumor metastasis. The degradation process thus creates the escape pathway by which single tumor cells leave their primary location and colonize surrounding areas. This degradation results from the low extracellular pH produced by tumor cells and relies on the secretion or membrane expression of acid-dependent proteases (MMPs and cathepsins). Soluble (MMP2, MMP9) or membrane-bound (MMP14) MMPs are key enzymes in tumor cell invasiveness, involved in both ECM and basement membrane degradation (187, 193, 253) and involved as well in the angiogenic sprouting (18, 53) . MMP activity is promoted by low extracellular pH localized at the front part of migrating cells. As stated above, NHE1 is one of the main actors of this extracellular acidification. While the acidification process appears as a crucial step to weaken and break the ECM barrier, the physical progression of aggressive tumor cells relies on the formation of ECM-degrading protrusions, called invadopodia, at the leading edge of the cells. NHE1 has been localized within these invadopodia (29) and this localization has been correlated with extracellular acidification and MMP expression and activity (88) , thus suggesting the invadopodia as the major sites of ECM digestion and NHE1 as the main channel involved in this process.
Voltage-gated sodium channels are highly expressed in epithelial tumors. In the MDA-MB-231 breast cancer cell line, the Na v 1.5 Na ϩ channel, by driving Na ϩ influx and depolarizing the cells, greatly increases NHE1 potency to promote extracellular acidification and tumor invasion (23, 24, 86) .
Calcium channels are also involved in the migration and invasion processes. Indeed, TRP channels, which mediate SOCE Ca 2ϩ entry and regulate intracellular [Ca 2ϩ ], especially TRPV2 (158) and TRPM8 (169), positively influence carcinoma invasion by upregulating MMP2 and MMP9 synthesis and production. Thus, MMP production may be an intracellular [Ca 2ϩ ]-dependent process. Interestingly, high concentrations of ATP are observed in the TME of most hypoxic solid tumors (181) . ATP acts as a signaling agent by activating plasma membrane ligand-gated receptors of the P2X family, namely, P2X 7 R cation channels promote migration and invasion, as shown in T47D breast cancer cells (253) . P2X 7 R cation channels mediate Ca 2ϩ influx in tumor cells thus contributing to the increase in intracellular [Ca 2ϩ ]. In the breast cancer cell line MDA-MB-435S, ATP activation of P2X 7 R cation channels activates Ca 2ϩ -dependent SK3-mediated potassium currents, thus favoring the elongation of cell protuberances, which, in turn, promote cell migration (110) . In this model, the P2X 7 Rpromoted invasive phenotype also relies on the activation of proteolytic enzymes, essentially cathepsin B. Correlatively, pharmacological inhibition or downregulation of P2X 7 R channels in PC-3M human prostate carcinoma-derived cell lines inhibit ATP-driven migration and invasion (193) . This Ca 2ϩ -dependent process requires activation of either PI3/Akt or ERK1/2 signaling pathway. It reduces the expression of proteins involved in the maintenance of cell-cell contacts (e.g., E-cadherin and claudin-1) and correlatively increases the expression of Snail (an inhibitor of E-cadherin), interleukin 8 (IL-8, a promoter of migration and angiogenesis), and MMPs, thus contributing to the invasion phenomenon. The metastasisand malignancy-promoting status of P2X 7 R, however, is still an important field in cancer research. Indeed, recent studies have been designed to explore the effects of P2X 7 R on tumor development and metastatic outcome in vivo. Hofman and collaborators (103) demonstrate that colitis-associated cancers (colon adenocarcinoma, colon carcinoma) are favored by P2X 7 R silencing or pharmacological inhibition. A different study reveals that P2X 7 R restricts tumor progression by developing antitumoral immunity (4).
Metastasis: transit in blood vessels and extravasation. Tumor cell metastasis occurs when the cells successfully escape from their primary location, overcome the step of transit in the circulation as unattached cells, and finally disseminate to their secondary sites by extravasation from the vessels and reattachment to a new ECM support.
Circulating tumor cells do not always survive long enough to metastasize. It is estimated that only 0.01% of the cells that enter the vasculature will eventually survive the harsh conditions to which they are submitted (87) . Tumor cells must resist anoikis whereby apoptosis is triggered by inadequate or loss of cell anchorage. Among the multiple signals involved in anoikis resistance, several types of ion channels have been described (137) .
Indeed, to effectively resist detachment-induced apoptosis, tumor cells utilize mechanisms that eventually limit the rise in intracellular [Ca 2ϩ ]. Ca 2ϩ channels are thus downregulated, especially those acting via SOCE (130) . Depletion in other Ca 2ϩ channels (TRPM2, TRPV6) also tends to reduce cell apoptosis (211 Tumor cells are subjected to mechanical forces resulting from the blood stream, especially in narrow capillaries. Mechanical stress is the main destruction pathway that tumor cells must avoid to be able to form metastases. To prevent destruction, they develop integrin-involving adhesion processes and eventually get attached to the endothelial bed of the vessel in which they are traveling (81) . This interaction between circulating tumor cells and endothelial cells is fundamental for the rest of the metastasis process, as it determines the site where the cells will eventually exit from the vessel, hence initiating the extravasation process. Gout and Huot (87) have described the whole process of extravasation. Briefly, this process involves a first step of tumor cell adhesion to endothelial cells, utilizing specific receptors. Tumor cells rolling along the endothelial layer characterize this "light adhesion" step. A second step of firmer cell attachment then takes place, mediated by cytokines and cell adhesion molecules. Extravasation (or diapedesis) finally occurs when the cells cross the endothelial barrier through cell-cell junctions. As for several steps of the tumorogenesis process, the importance of intracellular [Ca 2ϩ ] and of the associated Ca 2ϩ channels is also demonstrated for metastasis of tumor cells. Indeed, Orai1, the pore-forming component of the store-operated Ca 2ϩ channel and its associated STIM1 Ca 2ϩ sensor, is associated with cell migration, invasion, and metastasis in human breast carcinoma cells (256) . In vivo studies in a zebrafish model corroborate the importance of the Orai1/STIM1 partners and of SOCE Ca 2ϩ entry in the process of cell extravasation (262) . Indeed, inhibition of the store-operated Ca 2ϩ entry or knockdown of Orai1 in nasopharyngeal carcinoma cells prevents extravasation of the cells from vasculature in a zebrafish hematogenous metastasis model.
Finally, diapedesis is the result of tumor cells passing in between insufficiently tight endothelial cell junctions (due to damaged vasculature). The alterations in cell shape necessary for diapedesis are most likely explained by K ϩ and Cl Ϫ fluxes and by the following water fluxes. Indeed, it has been already shown that glioma cell migration and invasion are supported by K ϩ and Cl Ϫ channels, which, by governing transmembrane water movements and the resulting cell shape, are important for glioma invasion through narrow spaces (215) .
Colonization of the secondary site by the tumor is not simply a matter of gaining access to this site. Tumor cells will only be able to colonize compatible target tissues. The host tissue must then adapt to be able to foster the colonizing tumor cells; this is the concept of "premetastatic niche" (212) . Tumor cells must also adapt to their new stroma and become able to secrete all the molecules necessary for their efficient attachment and ulterior vascularization (91) . Hence, there are many barriers to overcome before the tumor actually metastasizes.
SIGMA-1 RECEPTOR: THE MAIN ORGANIZER?
In the present review, we will skip the long history of sigma-1 receptor (Sig-1R), which has been widely studied on the functional, pharmacological, structural, and mechanistic points of view for the last 30 -40 years (11, 148, 245) . Similarly, we will not open this discussion to the sigma-2 receptor, which has not been cloned yet, although it was shown to be involved in cancer development (234) . Instead, we will focus on the specific role of chaperone of Sig-1R that is of major interest in the context of cancer development.
Sig-1R is a 25-kDa, endoplasmic reticulum (ER)-resident, ligand-regulated protein, which is involved in many diseases, ranging from toxic substance addiction to stroke and cancer (10, 11, 148) . It is mainly present in normal brain, heart, and liver but is highly expressed in tumor cell lines and human cancer tissues of various origins, including lung, colon, prostate carcinomas, sarcomas, breast tumors, brain tumors, and melanomas (10, 11, 113, 173, 241) , in which it interferes with cell cycle and proliferation (10, 197) . Interestingly, in breast cancer cells, Sig-1R positively correlates with the metastatic grade of the cells, i.e., highly metastatic cells contain higher levels of Sig-1R mRNA and protein than their less aggressive counterparts (10) .
Sig-1R is anchored in the ER membrane, in a specific region called mitochondrion-associated ER membrane (MAM). At rest, it is in a "dormant" state, associated with a chaperone protein, called GRP78 or BiP (100) . BiP is a main regulator of ER function: it has a high Ca 2ϩ -buffering capacity and serves to store Ca 2ϩ , which is essential to many signaling pathways. Under specific ligand stimulation or under prolonged ER stress such as ER Ca 2ϩ depletion, Sig-1R is upregulated, dissociates from BiP, and becomes able to act as a chaperone (100) after translocation to other ER areas or to the plasma membrane (101) . In the plasma membrane, Sig-1R interacts with-and regulates the activity of-several ion channels (Ca 2ϩ , K ϩ , Na ϩ , Cl Ϫ ), receptors (NMDA receptor), or kinases (Src) (148) . In the context of cancer development, as we discussed earlier in this review, many ion channels of diverse classes (voltage-gated, calcium-gated, volume activated) are involved in a number of tumor cell processes. Voltage-gated ion channels are involved in cell processes including proliferation, apoptosis, angiogenesis, adhesion to ECM, and migration. Interestingly, Sig-1R interacts with most of these channels, as demonstrated in several works (12, 13, 126, 197) . Patch-clamp studies and Western blot assays in the presence of Sig-1R ligands [e.g., (ϩ)-pentazocine, igmesine, and 1,3-di(2-tolyl)guanidine (DTG)] were conducted in small cell lung cancer (SCLC)-derived cell lines (NCI-H146 and NCI-H209) and in T-cell leukemiaderived Jurkat cells. These studies demonstrate that ligand-mediated inhibition of Sig-1R results in cell cycle arrest in G 1 phase with no stimulation of apoptosis (197) . This effect correlates with the reduction of voltage-operated K ϩ currents in all these cell lines, indicating that Sig-1R-mediated cell growth arrest is the result of the negative regulation of K ϩ channels (197) . Cell cycle arrest also correlates with the negative modulation of volume-regulated chloride channels (VRCC), both effects leading to the overall inhibition of the regulated volume decrease (RVD) process, (196) , which is known to govern cell cycle progression and numerous cellular functions such as proliferation, apoptosis, migration, ѧ (202). The Xenopus oocyte system allowed direct reconstitution (in the absence of Sig-1R ligands) of the interaction that exists between Sig-1R and potassium channels (K v 1.4 and K v 1.5) and established that Sig-1R directly acts as an auxiliary subunit of a few channels to govern several cell functions (12) . To provide further evidence of this direct interaction, I participated in a study (47) showing that in chronic myeloid leukemia (CML)-derived cells (K562), which overexpress Sig-1R, the abnormally expressed cardiac K ϩ channel hERG coimmunoprecipitated with Sig-1R. In this model, Sig-1R extinction by a specific shRNA or Sig-1R inhibition by Sig-1R ligands led to the reduction of hERG K ϩ currents, whereas co-injection of both hERG and Sig-1R in Xenopus oocytes increased hERG current compared with oocytes injected with hERG alone. This modulation proceeds from the regulation of hERG channel maturation and stability, which is in agreement with the role of Sig-1R as a chaperone of hERG K ϩ channels in cancer cells (47) .
Recently, using the technique of atomic force microscopy, Sig-1R was shown to physically associate, in a fourfold symmetry (one channel molecule vs. four Sig-1R molecules), with the voltage-gated Na ϩ channel Na v 1.5 (13), previously proven to promote invasiveness in breast cancer cells (24, 86) . With the same technique, the same team demonstrated physical interaction between Sig-1R and acid-sensing ion channels [ASIC1a (36) ] and provided evidence of Sig-1R association with the heteromeric GluN1/GluN2A NMDA receptor, via specific binding of Sig-1R to the GluN1 subunit (14) .
These data raise the following question: how can an ER protein interact with plasma membrane ion channels of so many different families and govern so many cell functions in oncogenesis? A plausible explanation resides in the following observations: 1) Sig-1R is localized in ER, a cell area where Ca 2ϩ signaling is crucial; and 2) Sig-1R is highly mobile in the ER membrane and Sig-1R overexpression, cellular stress, or pharmacological treatment lead to dissociation of Sig-1R from its chaperone BiP and subsequent translocation to the plasma membrane (100, 149, 221) , where it interacts with its client proteins (ion channels, receptors). Indeed, during cancer progression, the tumor cells undergo harsh conditions (hypoxia, low pH, starvation in nutrients) or even treatments that create cell stress and alter ER protein expression levels or generate abnormal secretion of ER-resident chaperones (157) . Indeed, inasmuch as ER chaperones such as Sig-1R contribute to the correct folding of newly synthetized or conformationally distorted proteins, or to protect proteins that are prone to be misfolded, their role becomes crucial in case of cell stress. Moreover, it is worth pointing out that the BiP-Sig-1R association is tightly regulated in an ER Ca 2ϩ /Mn 2ϩ -dependent manner. Any cell signal that results in lowering ER Ca 2ϩ concentration below physiological concentration (0.5 mM) leads to disassembly of the two chaperones, thus increasing the activity of each (100) . Under cell stress conditions, Sig-1R stabilizes the conformation of type 3-IP 3 receptor in the ER, thus stimulating Ca 2ϩ transport from the ER to the mitochondria (100) and to the cytosol (252) . Hence, Sig-1R orchestrates Ca 2ϩ signaling between ER and mitochondria, by fueling the production of ATP by the mitochondria, which conversely regulates Ca 2ϩ concentration in the ER (99) . Sig-1R also maintains proper folding and proper function of the plasma membrane proteins challenged by cell stress: it thus plays a major role in cell survival (Fig. 3) . Sig-1R has since then been proposed as a modulator of inter-organelle signaling (220) .
Subsequently, several lines of evidence demonstrate that Sig-1R interacts with different types of proteins including ER stress sensors, cytokines, and ion channels and that this interaction constitutes the mechanism whereby Sig-1R governs cancer cell behavior in response to alterations of the tumor microenvironment. Sig-1R modulates cell survival (160), apoptosis (60, 151) and cell cycle (196, 197) . Recently, I participated in a study presenting evidence that Sig-1R is a key regulator of the signaling events that occur between the tumor cell and its microenvironment. Indeed, in chronic myeloid leukemia-and colon carcinoma-derived cells (resp. K562 and HCT-116 cells), we showed that extracellular matrix triggered a Sig-1R-dependent increase in cell adhesion, cell migration, cell invasiveness, as well as VEGF secretion (48) and that a hERG K ϩ channel-␤1 integrin interaction mediated these effects in both cell lines. Silencing of Sig-1R in K562 and HCT-116 cells resulted in in vivo reduction of angiogenesis, invasion, and extravasation (48) . Sig-1R thus appears as a major regulator of tumor development. Further studies are necessary to assess whether Sig-1R might be envisioned as a Fig. 3 . Schematic representation of plasma membrane ion channel chaperoning and Ca 2ϩ signaling enhancement by sigma-1 receptor (Sig-1R) in cancer cells. During cancer progression, tumor cells are submitted to stressful conditions caused by low PO2, low pH, and few nutrients. Under these conditions, Sig-1R (blue wide arrow), released from its ER cochaperone BiP, activates the ER IP3R3 Ca 2ϩ channel, thus enhancing Ca 2ϩ flux from the ER to the mitochondria and increasing the production of energy by the mitochondria. Sig-1R also stimulates the bcl2 oncogene transcription, which reduces reactive oxygen species (ROS) production by the mitochondria and is in favor of cell survival. Under prolonged conditions of stress, ER chaperones are upregulated; Sig-1R is overexpressed and translocates to the plasma membrane area where it becomes able to chaperone and activate membrane proteins such as ion channels (hERG, Nav1.5, ASIC1a, ь ь ь) or enzymes (e.g., Src kinase). VRCC, volume-regulated chloride channel. [Adapted after Su et al. (220), with permission from Elsevier.] therapeutic target and whether Sig-1R ligands might be designed as antitumoral treatments.
ANTIANGIOGENIC THERAPY AND THERAPY RESISTANCE
Cancer is one of the deadliest pathologies, with approximately 14 million of new cases and 8 million of cancer-related deaths in 2012; negative World Health Organization predictions expect annual cancer cases to rise from 14 million in 2012 to 22 million in the next two decades. Carcinomas (lung, liver, stomach, colorectal, breast, esophageal) are among the most common causes of cancer deaths http://www.who.int/mediacentre/factsheets/fs297/en/.
Conventional global antitumoral therapies (chemotherapies) are only partly efficient because of the lack of responsiveness of some cancers and because these therapies sometimes induce systemic toxicity or resistance, ending up in treatment discontinuation. For vascularized cancers, a more precise strategy of angiogenesis inhibition has been developed, which focuses on the neutralization of the effects of angiogenic factors (FGF, VEGF) or on the inhibition of their receptors (70, 122) . This strategy leads to vasculature destruction. Given the drawbacks of such therapies (89, 90) , which can lead to more severe conditions or even to death (194, 195) , solid tumor therapies evolved towards normalization rather than destruction of the abnormal vasculature, the objective being to restore a close to normal blood flux and PO 2 , to favor normal immune cell function and finally, to allow efficient delivery of anticancer agents (106, 109, 190, 219) . Thus, antiangiogenic therapies were used to treat several vascularized cancers in the past 40 years. However, too many carcinomas are still refractory to antiangiogenic-based treatments.
Hence, in parallel to existing therapeutic strategies, it is important to identify predictive biomarkers of stage and aggressiveness for the different types of tumors, as well as further targets for the development of complementary treatments to be used in combination with VEGF-targeted therapies. Carcinogenesis is a multistep process in which each step constitutes a potential angle of attack for a new therapeutic strategy development. Ion channels are implicated in the growth, migration, invasion, and metastasis of tumors and therefore cancers can be included in the category of "channelopathies" (pathologies characterized by alterations in channel function). Consequently, recent studies present ion channels as potential targets for the development of future treatments. Several factors are in favor of the use of ion channels as therapeutic targets: 1) cell expression of ion channels is often modified in cancers; 2) this expression varies with the type of tumor and, in a given type of tumor, with the specific step of tumor progression; and 3) ion channels are accessible from the extracellular side of the cell, and the potential pharmacological tools (available or yet to be designed) are multiple.
We do not intend here to review how ion channels can be targeted in each step of cancer development or in different cancers to design potential therapeutic strategies. Several excellent reviews have already been written from these standpoints (9, 49, 155, 203, 239) . Rather, we will take a few examples of global cancer-associated clinical dysfunctions in which ion channels may be targeted to restore normal function or diminish cancer-associated disagreements and, finally, to improve patient's condition.
Restoring a Less Toxic Microenvironment
Concomitant with gradual accumulation of mutations in tumor cells, changes in the physical parameters of the microenvironment also contribute to reinforce the cell aggressiveness. Among these physical changes, as discussed in the The Fate of New Tumors section of this review, the microenvironment undergoes hostile conditions characterized by low PO 2 , high interstitial pressure, low extracellular glucose, and high extracellular lactate-all of these create high extracellular acidity. Regulating the establishment of such harsh conditions would reduce the metastatic potential of tumor cells. Cancer therapies thus include trials based on the regulation of extracellular pH. They consist of systemic buffering using sodium bicarbonate to increase extracellular pH or take advantage of the proton transport systems involved in tumor cells (150) . For the latter, inhibition of carbonic anhydrases (especially CAIX), of the Na ϩ /H ϩ exchanger, using amiloride or EIPA, are efficient but have not been developed for clinical use. Conversely, inhibition of the vacuolar H ϩ -ATPase, using omeprazole (already used to suppress gastric acidity), was proven efficient as a pH normalizer in cancer treatment. Interestingly, the opposite treatment consisting in hyperacidification of tumor cells or of their microenvironment is also a promising treatment. Intracellular hyperacidification promotes tumor cell apoptosis whereas extracellular hyperacidification may provide an important tool to deliver therapeutic agents directly to the tumor site using acid-accumulating peptides (69).
Normalizing the Vasculature
Carcinoma progression is associated with the production, by tumoral and stromal cells, of angiogenic factors, which participate in the development of a nonproductive angiogenesis, owing to blood vessel disorganization and to vessel wall high permeability. Antiangiogenic treatments, which tend to block the development of new blood vessels and harvest the tumor from oxygen and nutrients, are inadequate or even counterproductive to treat cancers. Other targets are now under scrutiny, which could participate in the emerging process known as vascular normalization, and among these targets are ion channels. Physical properties of the ECM have been shown to influence normal and malignant cell behavior. Especially, angiogenic response is influenced by the stiffness of tumor ECM (134) . Ca 2ϩ influx is one of the main responses of endothelial cells to the mechanical stress resulting from the growth of new vessel tips in such a stiff environment. In a recent paper, it has been shown that in a model of mouse prostate adenocarcinoma, mechanosensitive transient receptor potential vanilloid 4 (TRPV4) calcium channels regulate angiogenesis and tumor vessel maturation by the regulation of tumor endothelial cell mechanosensitivity via the reduction in basal Rho activity (2) . This confirms that ion channels must be included in the set of molecules to be targeted in the design of the new tools aiming at normalizing vasculature, hence allowing better delivery of complementary antitumoral therapies. To further reinforce the biological relevance of Ca 2ϩ channels as molecular targets for antitumoral treatments, we can mention that all of the families of Ca 2ϩ channels have recently been the focus point of research demonstrating the involvement of these channels in pro-angiogenic processes. Many of these channels are now the object of patents that describe the use of modulators of their function to treat the symptoms associated with cancer, i.e., proliferation, angiogenesis, and metastasis (for review, see ref. 163 ). The use of K ϩ channel or pH modulators to fight cancer development has been patented as well (49, 198) .
Fighting Cancer-Induced Pain
Cancer-related pain is one of the most devastating side effects of tumor development. Indeed, hypoxia and, consequently, tumor acidosis are known to be responsible for the generation of pain (108) . Cancer-related pain can also be the result of tumor metastasis, especially in the case of bone dissemination. Indeed, cytokines produced by the tumor cells or by the bone microenvironment activate osteoclasts and thus contribute to the signaling of cancer-associated pain in bones (225) . Antitumoral treatment administration can, by itself, be a factor of pain, whether the treatment is traditional chemotherapy, radiation, or surgery.
Moreover, it now seems that, except for morphine, for which the study results are not conclusive, conventional pain-reducing therapies (NSAIDs, cannabinoids, opioids, GABA-ergic drugs) may have a negative impact on cancer evolution (135) . Consequently, the research of other analgesics and their targets is required. Current research on this topic focuses on ion channels associated with pain, such as ASICs (57, 258), especially ASIC3 (56), and such as TRP channels of several subfamilies, especially TRPV1 (192) . Indeed, both types of channels are known to be expressed in sensory neurons and to be activated by an acid load. These channels represent relevant targets for the future development of new analgesics. Treatments based on TRPV1 pharmacological inhibitors are already being clinically tested, with some showing promising results (22 (242) . This field of research is still wide open and progressing very quickly. It is interesting to note that most of the ion channels involved in the perception of pain are also implicated in one step or another of tumor development. This leaves open the possibility that a specific treatment designed against an ion channel to treat cancer-associated pain might also be used to prevent cancer progression. In particular, cannabinoids demonstrate antitumoral effect in several cancer types (hepatocellular carcinoma, ccRCC, etc.), which is not mediated by the regular CB1 and CB2 cannabinoid receptors (131, 235) . Since cannabinoids can bind to many different ion channel types, such as GPCR, NMDA receptors, and GABA A receptors (182) , any of them can mediate the effect of cannabinoids in tumor cells, thus shedding a new light on the yet unexplained antioncogenic effect of cannabinoids.
In this topic, it is tempting to propose the potential development of Sig-1R ligands as treatments to fight cancer-induced pain. Indeed, as we mentioned earlier, Sig-1R promotes the action of ASIC channels, which are involved with nociception (36). Sig-1R-inhibiting agents might be a way to obtain relief in this matter.
CONCLUSION
A new concept in oncogenesis has emerged in the past 20 to 25 years, which states that ion channels and transporters regulate different aspects of the neoplastic cell physiology. A growing body of evidence now demonstrates that they govern the so-called "hallmarks of cancer." As for neoangiogenesis, ion channels are involved at all stages, in tumor cells, as well as endothelial cells or stromal cells. Ion channels thus represent a new and promising field of research concerning the development of novel therapeutic agents. TRP channels for instance, which are highly expressed in endothelial cells and involved in thermosensation, osmoregulation, and mechanoreception, are under current scrutiny for novel therapeutic strategy developments. Similarly, whereas monocarboxylate transporters (MCT1 and MCT4) have now emerged as anticancer targets, the lactate shuttle mechanism governing tumor cell pH regulation is still under study (55, 59). However, it is important to take into account that most ion channels, though overexpressed in many cancer types, still exist in healthy organs. The use of ion channel inhibitor-based therapies might thus induce many side effects, which will need to be carefully prevented or minimized. As an example, blocking hERG1 K ϩ channel prevents the angiogenic switch in colorectal cancer and, in turn, reduces metastasis (46) . However, hERG1 is one of the main heart-expressed K ϩ channels, which certainly hinders the use of any of the current hERG1-targeted molecules as a cancer therapeutic agent. It might thus be important to develop noncardiotoxic hERG1 blockers to be used as complementary antiangiogenic treatments. The ion channel-based antitumoral therapies, though very attractive and potentially powerful, probably need more research time to be carefully designed for safe clinical use. It might be more fruitful to develop pharmacological treatments against Sig-1R, taking into account that this protein is present in many tissues (central nervous system, lung, liver, pancreas, spleen) in membrane compartments. Targeted pharmacological action on Sig-1R at the MAM or at the plasma membrane represents a potential new axis for the development of therapies against numerous diseases including cancer.
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